Key Details
Price
$0.67Annual Revenue
$1.10 MAnnual EPS
-$5.50Annual ROE
-82.11%Beta
1.40Events Calendar
Next earnings date:
Mar 27, 2025Recent quarterly earnings:
Nov 13, 2024Recent annual earnings:
Mar 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Sept 03, 2024Analyst ratings
Recent major analysts updates
Screeners with MTNB included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Signs non-binding term sheet granting global rights to develop and commercialize oral MAT2203 for invasive aspergillosis and potentially other invasive fungal infections
Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Call Transcript
Matinas BioPharma Holdings, Inc. (NYSE:MTNB ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Jody Cain - LHA IR Jerry Jabbour - CEO Terri Matkovits - CDO Terry Ferguson - CMO Keith Kucinski - CFO Conference Call Participants Julian Harrison - BTIG Operator Welcome to the Matinas BioPharma Third Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Let's talk penny stocks, those under-five-dollar shares that buzz with potential. They're nimble, sensitive to the slightest news, and can pivot on a dime.
BEDMINSTER, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (LNC) platform technology, announces that Jerome D. Jabbour, Chief Executive Officer, will present a company overview and hold meetings with institutional investors at two upcoming investment conferences:
Matinas Biopharma Holdings, Inc. (MTNB) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
BEDMINSTER, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announces that it will report first quarter 2023 financial results after market close on Wednesday, May 10, 2023. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).
FAQ
- What is the primary business of Matinas BioPharma Holdings?
- What is the ticker symbol for Matinas BioPharma Holdings?
- Does Matinas BioPharma Holdings pay dividends?
- What sector is Matinas BioPharma Holdings in?
- What industry is Matinas BioPharma Holdings in?
- What country is Matinas BioPharma Holdings based in?
- When did Matinas BioPharma Holdings go public?
- Is Matinas BioPharma Holdings in the S&P 500?
- Is Matinas BioPharma Holdings in the NASDAQ 100?
- Is Matinas BioPharma Holdings in the Dow Jones?
- When was Matinas BioPharma Holdings's last earnings report?
- When does Matinas BioPharma Holdings report earnings?
- Should I buy Matinas BioPharma Holdings stock now?